BioMérieux

The FilmArray ME Panel received a de novo clearance from the US Food and Drug Administration in October.

The diagnostics company reported organic sales increased 4 percent in Q4 and 7 percent in 2015, and set a growth target of 6 percent to 8 percent for 2016. 

The molecular diagnostics developer will use the money to continue expanding its commercial presence in the cancer diagnostics market.

The FilmArray Torch has up to 12 modules per system and can process up to 262 patient samples per day using the firm's syndromic panel tests.

The platform meets the needs of customers preferring molecular testing over immunoassays, and enters a dynamic and rapidly expanding food testing market.

BioMérieux plans to use Applied Maths' solutions to support EpiSeq, its newly launched microbial sequencing service.

Their approach detects resistance to carbapenems, drugs commonly used in hospitals and in patients with infections already resistant to other antibiotics.

A study of samples from Sierra Leone and the UK of heat-inactivated whole blood showed high sensitivity and specificity using the FilmArray BioThreat-E test.

Third quarter revenues increased 16 percent on a reported basis year over year driven in part by a 60 percent spike in molecular biology sales.

The FilmArray ME Panel is the first nucleic acid amplification test to detect multiple pathogens from a single cerebrospinal fluid sample. 

Pages

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.